

**Sudan, Republic of**  
**Support for Injection Safety Devices**  
**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b>	Sudan, Republic of						
<b>2. Grant number(s):</b>	17-SDN-32a-X, 18-SDN-32a-X, 19-SDN-32a-X, 20-SDN-32a-X						
<b>3. Date of Decision Letter:</b>	11-Jul-19						
<b>4. Date of the Partnership Framework Agreement:</b>	December 10, 2013						
<b>5. Programme title:</b>	Injection Safety Devices <sup>1</sup>						
<b>6. Programme Duration:<sup>2</sup></b>	2017-2020						
<b>7. Programme Budget (indicative):<sup>3</sup></b>	<b>(subject to the terms of the Partnership Framework Agreement, if applicable)</b>						
	<b>2017-2018</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	1,530,314	1,037,500	481,000	-	-	-	3,048,814
<b>8. Indicative Annual Amounts:<sup>4</sup></b>	<b>(subject to the terms of the Partnership Framework Agreement, if applicable)<sup>4</sup></b>						
<b>Total injection safety devices to be purchased with Gavi funds in each year</b>	<b>2017-2018</b>	<b>2019</b>	<b>2020</b>				
Number of AD syringes		21,447,100	-				
Number of re-constitution syringes		1,267,900	-				
Number of safety boxes		249,925	-				
<b>Annual Amounts for injection safety devices for all Gavi vaccines (US\$)</b>	<b>1,530,314</b>	<b>1,037,500</b>	<b>-</b>				
<b>Injection safety devices to be purchased with Gavi funds in each year, by type of support</b>							
<i>Injection safety devices to be purchased with Gavi funds in each year, by type of support</i>							
<b>New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID - Routine</b>		<b>2019</b>	<b>2020</b>				
Number of AD syringes		1,711,000	-				
Number of re-constitution syringes		-	-				
Number of safety boxes		18,825	-				
Annual Amounts for injection safety devices for vaccine (US\$)		77,500	-				

<sup>1</sup>This does not include vaccines.

<sup>2</sup>This is the entire duration of the Programme.

<sup>3</sup>This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>4</sup>This is the amount that Gavi has approved.

<b>New Vaccine Support (NVS), Meningococcal type A, 10 dose(s) per vial, LYOPHILISED - Routine</b>	<b>2019</b>	<b>2020</b>
Number of AD syringes	1,339,300	-
Number of re-constitution syringes	187,600	-
Number of safety boxes	16,800	-
Annual Amounts for injection safety devices for vaccine (US\$)	70,500	-
<b>New Vaccine Support (NVS), Pneumococcal (PCV13), 4 dose(s) per vial, LIQUID - Routine</b>	<b>2019</b>	<b>2020</b>
Number of AD syringes	4,439,200	-
Number of re-constitution syringes	-	-
Number of safety boxes	48,850	-
Annual Amounts for injection safety devices for vaccine (US\$)	201,000	-
<b>New Vaccine Support (NVS), Pentavalent, 1 dose(s) per vial, LIQUID - Routine</b>	<b>2019</b>	<b>2020</b>
Number of AD syringes	4,225,800	-
Number of re-constitution syringes	-	-
Number of safety boxes	46,500	-
Annual Amounts for injection safety devices for vaccine (US\$)	191,500	-
<b>New Vaccine Support (NVS), Yellow Fever, 10 dose(s) per vial, LYOPHILISED - Campaign</b>	<b>2019</b>	<b>2020</b>
Number of AD syringes	9,731,800	-
Number of re-constitution syringes	1,080,300	-
Number of safety boxes	118,950	-
Annual Amounts for injection safety devices for vaccine (US\$)	497,000	-

**9. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**10. Self-procurement:** Not applicable

**11. Co-financing obligations:**

Co-financing requirements are listed in the relevant vaccine Decision Letter.

**On behalf of Gavi**



Pascal Bijleveld  
Managing Director, Country Programmes a.i.